Health
Opioid-related deaths between 2019 and 2021 across 9 Canadian provinces and territories
|
|
Abstract
Background: The drug toxicity crisis continues to accelerate across Canada, with rapid increases in opioid-related harms following the onset of the COVID-19 pandemic. We sought to describe trends in the burden of opioid-related deaths across Canada throughout the pandemic, comparing these trends by province or territory, age, and sex.
Methods: We conducted a repeated cross-sectional analysis of accidental opioid-related deaths between Jan. 1, 2019, and Dec. 31, 2021, across 9 Canadian provinces and territories using aggregated national data. Our primary measure was the burden of premature opioid-related death, measured by potential years of life lost. Our secondary measure was the proportion of all deaths attributable to opioids; we used the Cochrane–Armitage test for trend to compare proportions.
Results: Between 2019 and 2021, the annual number of opioid-related deaths increased from 3007 to 6222 and years of life lost increased from 126 115 to 256 336 (from 3.5 to 7.0 yr of life lost per 1000 population). In 2021, the highest number of years of life lost was among males (181 525 yr) and people aged 30–39 years (87 045 yr). In 2019, we found that 1.7% of all deaths among those younger than 85 years were related to opioids, rising to 3.2% in 2021. Significant increases in the proportion of deaths related to opioids were observed across all age groups (p < 0.001), representing 29.3% and 29.0% of deaths among people aged 20–29 and 30–39 years in 2021, respectively.
Interpretation: Across Canada, the burden of premature opioid-related deaths doubled between 2019 and 2021, representing more than one-quarter of deaths among younger adults. The disproportionate loss of life in this demographic group highlights the critical need for targeted prevention efforts.
In Canada, the COVID-19 pandemic occurred in the midst of a growing drug toxicity crisis. Before the emergence of COVID-19, the number of accidental opioid-related deaths across Canada rose from 2470 in 2016 to 3447 in 2019.1 This was accompanied by rising opioid-related hospital admissions1 and growing infectious complications associated with substance use.2 Although both prescription and unregulated opioids contribute to toxicity deaths,3 the relative contribution of these substances has changed considerably over time, with fentanyl from the unregulated drug supply involved in more than 80% of opioid-related deaths in recent years (2020 to early 2023).1 In 2021, almost 37 million people lived in Canada across 13 provinces and territories, with almost 40% residing in the province of Ontario,4 where the first 6 months of the pandemic saw an estimated 17 843 additional years of life lost (YLL) from opioid-related premature death.5
The observed acceleration in opioid-related harm across Canada has been attributed in part to public health measures implemented to curb the spread of SARS-CoV-2, including reduced access to harm reduction programs and border restrictions that may have increased the toxicity of the drug supply.6–8 In addition, for many, the pandemic exacerbated feelings of anxiety, uncertainty, and loneliness, contributing to increased substance use globally.9–12 The intersection of the COVID-19 pandemic with the drug toxicity crisis in Canada has created an urgent need to better understand the patterns of opioid-related deaths across the country to inform targeted public health responses. Therefore, we sought to describe trends in premature opioid-related deaths between 2019 and 2021 across 9 Canadian provinces and territories.
Methods
Study design and setting
We conducted a repeated cross-sectional analysis of all opioid-related deaths in 9 Canadian provinces and territories, with data collected at annual intervals between Jan. 1, 2019, and Dec. 31, 2021.13 We reported this study using the Reporting of Studies Conducted using Observational Routinely-Collected Data (RECORD) checklist.14
Data sources
We used publicly available, aggregate data from the Public Health Agency of Canada summarizing the annual counts of all accidental opioid-related deaths for each province and territory in Canada.1 These data capture all opioid-related deaths with completed and ongoing investigations (in all regions except for Saskatchewan, which includes only completed investigations) in which the coroner or medical examiner determined that an opioid directly contributed to an unintentional death. We included all provinces and territories for which age- and sex-stratified data were available at the time of the study; these were British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, Quebec, New Brunswick, Nova Scotia, and the Northwest Territories, representing 98.0% of Canada’s population.15 Additional information on the reporting of available data by province and territory can be found in Appendix 1, eTable 1, available at www.cmaj.ca/lookup/doi/10.1503/cmaj.231339/tab-related-content. Stratified data from Prince Edward Island, Nunavut, Newfoundland and Labrador, and the Yukon in all years were unavailable because of institutional privacy requirements requiring data suppression for cell sizes less than 5. We identified the annual population size of each province and territory and the national number of all-cause deaths by age and sex using deidentified, aggregated, publicly available data from Statistics Canada.15,16 We used the 2019–2021 Statistics Canada single-year life table estimates for males and females to calculate the average life expectancy within each age group for each year of the study period.17
Statistical analysis
Our primary study measures were annual counts and crude rates of opioid-related deaths and the burden of premature accidental opioid-related deaths, quantified by calculating the YLL using methods adapted from the Global Burden of Disease Study18 and stratified by sex and prespecified age groups (0–19 yr, 20–29 yr, 30–39 yr, 40–49 yr, 50–59 yr, 60–84 yr). We calculated the YLL separately within each stratum of sex by age group by multiplying the number of opioid-related deaths by the average remaining life expectancy at the midpoint of each age group. Given the aggregated nature of the data, we were unable to calculate the average age at death or adjust for comorbidities. We also applied an upper age limit of 84 years, as previous research showed that the absolute number and proportion of opioid-related deaths among people aged 85 years and older is small.19,20 We did not apply age-related weighting or discounting to the life expectancy estimates in our calculations, as recommended by the World Health Organization.18 We used the population of each province and territory to calculate crude rates of opioid-related deaths per million population and the YLL per 1000 population, and reported all metrics overall and stratified by each region.
Our secondary measure was the proportion of all-cause deaths in each age group attributable to opioids, using national and provincial age-stratified counts of opioid-related deaths with all-cause deaths as the denominator. Within each age group, we used the Cochrane–Armitage test for trend with Monte-Carlo estimates to assess whether the proportion of deaths attributable to opioids increased significantly between 2019 and 2021.
In a post hoc analysis, we conducted a time-series analysis using an interventional autoregressive integrated moving average (ARIMA) model to examine the impact of the declaration of the COVID-19 state of emergency in the first quarter of 2020 on rates of overall opioid-related deaths (per 100 000 population) between Jan. 1, 2016, and Dec. 31, 2022. We extended our study period to allow for sufficient data points to conduct the analysis. We modelled the onset of the COVID-19 pandemic using a ramp transfer function, given its anticipated gradual impact on rates of opioid-related deaths, after differencing the series to achieve stationarity, as confirmed with the Dickey–Fuller test. We explored seasonality and used model diagnostics to select the final, optimal model using the Ljung–Box χ2 test for white noise to ensure no significant autocorrelation in model residuals was present.
We conducted all analyses using Microsoft Excel (2022) and SAS version 9.4 (SAS institute).
Sensitivity analyses
We conducted 2 sensitivity analyses to assess the robustness of our results. First, because the average age at death was not available within each age group, we repeated our overall YLL calculations using the average age at death for all accidental opioid-related deaths in each age group in the United States (Appendix 1, eTable 2). These data are reported publicly from the US Centers for Disease Control and Prevention WONDER Multiple Cause of Death Database, which includes national data on all-cause deaths from information captured on completed death certificates.21 Second, at the time of our analysis, a large number of deaths in BC (n = 2346) were under investigation by the coroner and as such were not included in the age-stratified counts of opioid-related deaths, following BC reporting requirements. To investigate whether these missing deaths influenced our overall results, we reassessed the primary and secondary measures excluding all data from BC.
Ethics approval
Given the aggregated nature of the data used, this study received a research ethics board exemption from the Unity Health Toronto Research Ethics Board.
Results
Between Jan. 1, 2019, and Dec. 31, 2021, the number of accidental opioid-related deaths increased 107%, from 3007 to 6222 deaths per year, across the 9 Canadian provinces and territories included in our analysis (Table 1). Overall, the annual YLL from opioid-related deaths doubled over the study period, rising from 126 115 (3.5 YLL per 1000) in 2019 to 256 336 (7.0 YLL per 1000) in 2021 (Figure 1). In 2021, the highest burden of deaths was observed among males (181 525 YLL, 9.9 YLL per 1000) and young adults aged 20–29 years (64 127 YLL, 12.8 YLL per 1000) and 30–39 years (87 045 YLL, 16.5 YLL per 1000). Each year, more than 70% of all opioid-related deaths occurred among males (73.9% in 2021) and around 25% of deaths occurred among people between the ages of 30 and 39 years (29.5% in 2021). The YLL in each province and territory, stratified by age, sex, and year, can be found in Appendix 1, eTable 3. The annual increases by age and sex in each province and territory were generally consistent with our overall analysis. However, the observed changes in YLL over time varied geographically, ranging from a 4.7-fold increase in Manitoba (2434 YLL in 2019 to 11 543 YLL in 2021) to a 0.8-fold decrease in Nova Scotia (1581 YLL in 2019 to 1324 YLL in 2021). In 2021, the rate of YLL ranged from a low of 1.4 per 1000 in Nova Scotia to a high of 15.6 per 1000 in Alberta; the absolute number of YLL ranged from 93 in the Northwest Territories to 111 633 in Ontario.
Table 1:
Years of life lost (YLLs) from accidental opioid-related deaths across 9 Canadian provinces and territories between 2019 and 2021
<a href=”https://www.cmaj.ca/content/cmaj/196/14/E469/F1.large.jpg?width=800&height=600&carousel=1″ title=”Years of life lost per 1000 population across 9 Canadian provinces and territories from 2019 to 2021. *Includes only opioid-related deaths with completed investigations by the coroner; trends should be interpreted with caution as a substantial number of opioid-related deaths in British Columbia were still under investigation at the time of analysis.” class=”highwire-fragment fragment-images colorbox-load” rel=”gallery-fragment-images-857547093″ data-figure-caption=”
” data-icon-position data-hide-link-title=”0″>
Figure 1:
Years of life lost per 1000 population across 9 Canadian provinces and territories from 2019 to 2021. *Includes only opioid-related deaths with completed investigations by the coroner; trends should be interpreted with caution as a substantial number of opioid-related deaths in British Columbia were still under investigation at the time of analysis.
Proportion of all-cause deaths attributable to opioids
Between 2019 and 2021, the average percentage of all deaths attributed to opioids increased across all age groups (Figure 2). In 2019, 3007 (1.7%) of 173 720 deaths among people younger than 85 years were related to opioids, increasing to 6222 (3.2%) of 195 156 deaths in 2021 (p < 0.001). The largest relative increase between 2019 and 2021 was among people aged 30–39 years (50.3% increase, from 19.3% to 29.0% of deaths), followed by those aged 20–29 years (48.0% increase, from 19.8% to 29.3%). Results from the Cochrane–Armitage test for trend showed that this increase was significant overall and across all age groups in Canada (p < 0.001). Although the percentage of deaths attributable to opioids varied geographically, in general, this proportion was highest among people aged 20–39 years in each province and territory (Figure 3 and Appendix 1, eTable 4).
<a href=”https://www.cmaj.ca/content/cmaj/196/14/E469/F2.large.jpg?width=800&height=600&carousel=1″ title=”Proportion of all-cause deaths attributable to opioids across 9 Canadian provinces and territories, by year and age group, from 2019 to 2021.” class=”highwire-fragment fragment-images colorbox-load” rel=”gallery-fragment-images-857547093″ data-figure-caption=”
” data-icon-position data-hide-link-title=”0″>
Figure 2:
Proportion of all-cause deaths attributable to opioids across 9 Canadian provinces and territories, by year and age group, from 2019 to 2021.
<a href=”https://www.cmaj.ca/content/cmaj/196/14/E469/F3.large.jpg?width=800&height=600&carousel=1″ title=”Proportion of all-cause deaths attributable to opioids in 2021, by age and province or territory.*Includes only opioid-related deaths with completed investigations by the coroner; trends should be interpreted with caution as a substantial number of opioid-related deaths in 2021 in British Columbia (n = 1398) were still under investigation at the time of analysis.” class=”highwire-fragment fragment-images colorbox-load” rel=”gallery-fragment-images-857547093″ data-figure-caption=”
” data-icon-position data-hide-link-title=”0″>
Figure 3:
Proportion of all-cause deaths attributable to opioids in 2021, by age and province or territory.*Includes only opioid-related deaths with completed investigations by the coroner; trends should be interpreted with caution as a substantial number of opioid-related deaths in 2021 in British Columbia (n = 1398) were still under investigation at the time of analysis.
Time-series analysis
Between the first quarter of 2016 and the last quarter of 2022, the quarterly rate of opioid-related deaths increased 187.5%, from 1.6 to 4.6 per 100 000 population (Figure 4). After the declaration of a pandemic-related state of emergency in the first quarter of 2020, we observed a significant ramp increase of 0.27 (95% confidence interval 0.05–0.48) per 100 000 population quarterly in the overall rate of opioid-related deaths (p = 0.02).
<a href=”https://www.cmaj.ca/content/cmaj/196/14/E469/F4.large.jpg?width=800&height=600&carousel=1″ title=”Quarterly rate of opioid-related deaths in 9 Canadian provinces and territories, 2016–2022.*Vertical bar represents the declaration of a pandemic-related state of emergency for COVID-19. Note: Includes opioid-related deaths with both completed and ongoing investigations by the coroner in all provinces or territories except for Saskatchewan.” class=”highwire-fragment fragment-images colorbox-load” rel=”gallery-fragment-images-857547093″ data-figure-caption=”
” data-icon-position data-hide-link-title=”0″>
Figure 4:
Quarterly rate of opioid-related deaths in 9 Canadian provinces and territories, 2016–2022.*Vertical bar represents the declaration of a pandemic-related state of emergency for COVID-19. Note: Includes opioid-related deaths with both completed and ongoing investigations by the coroner in all provinces or territories except for Saskatchewan.
Sensitivity analyses
In our first sensitivity analysis, using the US average age at time of opioid-related death, results were consistent with our primary analysis (< 1.0% change in YLL each year) (Appendix 1, eTable 5). This provides reassurance that using the midpoint for each age group to adjust for age at death did not meaningfully affect our results. In our second sensitivity analysis, excluding all data from BC, the overall YLL observed in 2021 decreased by 13.5%; however, the YLL rate per 1000 population remained the same as in our primary analysis (7.0 per 1000 population across Canada in 2021) (Appendix 1, eTable 6). Further, the percentage of deaths attributed to opioids across age groups remained fairly consistent with those in our primary analysis (Appendix 1, eTable 7).
Interpretation
We found significant increases in the burden of opioid-related deaths between Jan. 1, 2019, and Dec. 31, 2021, with more than 250 000 years of life lost in 2021 alone, representing 1 in every 31 deaths among people younger than 85 years. Furthermore, the COVID-19 pandemic–related state of emergency was associated with a significant increase in the rate of opioid-related deaths. The increases in opioid-related deaths observed between 2019 and 2020 varied considerably by province and territory, rising 359.3% and 133.0% in Manitoba and Saskatchewan, respectively. This may reflect a more recent shift to fentanyl-related deaths in these provinces, as COVID-19 may have resulted in a more volatile unregulated drug supply.6,8 This aligns with data from Saskatchewan, where the number of drug toxicity deaths involving fentanyl increased 281.4% between 2019 and 2020.22 Similarly, in Manitoba, 70% of opioid toxicity deaths in 2019 had fentanyl or fentanyl analogues detected, increasing to 86% in 2020.1 In BC, 86% of all deaths in BC related to unregulated drugs had fentanyl detected in 2018.23 In contrast, a study conducted in Australia observed a 24% decrease in fentanyl-related deaths each year between 2015 and 2020.24 The increased detection of fentanyl in opioid-related deaths in Canada highlights the need for expansion of harm-reduction programs, including improved access to drug-checking services, supervised consumption sites, and treatment for substance use disorders. Given the rapidly evolving nature of the drug toxicity crisis, a public safety response is urgently required and may include continued funding of safer opioid supply programs that were expanded beginning in March 2020,25 improved flexibility in take-home doses of opioid agonist treatment,26 and enhanced training for health care workers, harm reduction workers, and people who use drugs on appropriate responses to opioid toxicities involving polysubstance use.27,28
Our findings add to those that characterized trends in the burden of opioid-related deaths before the pandemic. In Canada, the YLL from opioid-related deaths increased by 142% over the 24-year period from 1990 to 2014,29 compared with a 50% increase observed over just 3 years in our study. In comparison, after the first COVID-19 lockdown in England, overall opioid-related deaths decreased from an average of 125 to 117 deaths per month between 2019 and 2021.30 Although we observed significant increases in opioid-related deaths overall, this was especially pronounced among males and younger adults aged 30–39 years, representing 181 525 YLL (9.9 YLL per 1000) and 87 045 YLL (16.5 YLL per 1000), respectively, in 2021. The disproportionate burden of premature deaths among males and younger adults is consistent with previous findings from Ontario and the US.31–33 In 2015, the highest burden of opioid-related deaths in Ontario was among people aged 25–34 years in terms of proportion of deaths, YLL rate and total YLL (8375 YLL);31 people aged 24–35 years and males accounted for 20% and 68%, respectively, of all opioid-related deaths in the US in 2016.32 During the first 6 months of the pandemic in Ontario, a 320% increase in opioid-related deaths was observed among people younger than 35 years, with males accounting for three-quarters of all deaths.5 The sustained high rates of opioid-related harm observed among these demographic groups highlight the urgent need for low-barrier access to harm-reduction programs tailored to unique gender- and age-related needs.
In addition to experiencing substantial reductions in access to social supports and health care services during the pandemic, people who use drugs reported changes in patterns of drug use, including more frequently using drugs alone and a shift toward increased inhalation of drugs, which are both risk factors for opioid toxicities.34–37 The toll of premature opioid-related deaths observed in our study can also be contextualized in comparison with other leading causes of death. In 2019, we observed 126 115 YLL from opioid-related deaths overall, exceeding estimates from the Global Burden of Disease Study for unintentional injuries excluding accidental drug toxicities (118 836 YLL), cirrhosis and other chronic liver diseases (121 884 YLL), and diabetes mellitus (102 342 YLL) for people younger than 85 years in Canada.38
Limitations
We were unable to study 4 provinces and territories, for which the numbers of opioid-related deaths were suppressed because of small counts (< 5). We did have access to data on all opioid-related deaths with ongoing investigations by the coroner in BC (n = 2346) from the stratified data used in our analyses, with the exception of the time-series analysis. Our sensitivity analyses suggest that the demographic distribution of these deaths follow a pattern similar to our overall results, and their exclusion is therefore unlikely to bias our analyses. Nonetheless, the results from BC should be interpreted with caution, particularly in 2021, given the high number of ongoing investigations (n = 1398), which may help to explain the decrease in deaths observed from 2020 to 2021. Thus, we expect that our overall findings are an underestimate of the total burden of opioid-related death. Information on age at death was unavailable, leading us to apply an upper age limit of 84 years in our calculations. However, previous research showed that opioid-related deaths among those aged 85 years and older are uncommon, and the consistency of our sensitivity analysis is reassuring. We were unable to adjust for comorbidities in our YLL calculations. Given that some people may use opioids to treat pain associated with chronic diseases resulting in lower life expectancies, our YLL estimates may be overestimated. Finally, with the exception of Saskatchewan, all data on deaths include ongoing investigations and are therefore considered preliminary and subject to change. We anticipate that the number of opioid-related deaths under investigation in Saskatchewan is low22 and is unlikely to have substantially influenced our findings.
Conclusion
Between 2019 and 2021, the burden of premature death from accidental opioid toxicities in Canada dramatically increased, especially in Alberta, Saskatchewan, and Manitoba. In 2021, more than 70% of opioid-related deaths occurred among males and about 30% occurred among people aged 30–39 years, representing 1 in every 4 deaths in this age group. The disproportionate rates of opioid-related deaths observed in these demographic groups highlight the critical need for the expansion of targeted harm reduction–based policies and programs across Canada.
Footnotes
-
Competing interests: David Juurlink is a member of Physicians for Responsible Opioid Prescribing and the American College of Medical Toxicology. Both groups have publicly available positions on this issue. He has also received payment from law firms for lectures and medicolegal opinions regarding the safety and effectiveness of analgesics, including opioids. Mina Tadrous reports consulting fees from Health Canada and the Canadian Agency for Drugs and Technologies in Health (CADTH). Tara Gomes reports funding from the Ontario College of Pharmacists and CADTH, consulting fees from the Province of British Columbia, honoraria from Indigenous Services Canada, and payment for expert testimony from the Office of the Chief Coroner of Ontario. No other competing interests were declared.
-
This article has been peer reviewed.
-
Contributors: All of the authors contributed to the concept and design. Shaleesa Ledlie contributed to data analysis. All of the authors contributed to data interpretation. Shaleesa Ledlie drafted the manuscript. All of the authors reviewed the manuscript critically for important intellectual content, gave final approval of the version to be published, and agreed to be accountable for all aspects of the work.
-
Funding: This work was supported by grants from the Ontario Ministry of Health (no. 0691) and the Canadian Institutes of Health Research (no. 178163). Shaleesa Ledlie is supported by an Ontario Graduate Scholarship and the Network for Improving Health Systems Trainee Award. Tara Gomes is supported by a Tier 2 Canada Research Chair.
-
Data sharing: The opioid-related death data used in this study are publicly available from the Public Health Agency of Canada and Statistics Canada. Program files can be made available by reasonable request to the corresponding author.
- Accepted February 28, 2024.
This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/
A business plan for a new BC Cancer Centre at Nanaimo Regional General Hospital has been approved by the province.
Health Minister Adrian Dix says the state-of-the-art cancer facility will benefit patients in Nanaimo and the surrounding region through the latest medical technology.
The facility will have 12 exam rooms, four consultation rooms and space for medical physicists and radiation therapists, medical imaging and radiation treatment of cancer patients.
The procurement process is underway, and construction is expected to begin in 2025 and be complete in 2028.
Upgrades to NRGH have also been approved, such as a new single-storey addition to the ambulatory care building and expanded pharmacy.
Dix says Nanaimo’s population is growing rapidly and aging, and stronger health services in the region, so people get the health care they need closer to home.
Health
Outdated cancer screening guidelines jeopardizing early detection, doctors say – Powell River Peak
A group of doctors say Canadian cancer screening guidelines set by a national task force are out-of-date and putting people at risk because their cancers aren’t detected early enough.
“I’m faced with treating too many patients dying of prostate cancer on a daily basis due to delayed diagnosis,” Dr. Fred Saad, a urological oncologist and director of prostate cancer research at the Montreal Cancer Institute, said at a news conference in Ottawa on Monday.
The Canadian Task Force on Preventive Health Care, established by the Public Health Agency of Canada, sets clinical guidelines to help family doctors and nurse practitioners decide whether and when to recommend screening and other prevention and early detection health-care measures to their patients.
Its members include primary-care physicians and nurse practitioners, as well as specialists, a spokesperson for the task force said in an email Monday.
But Saad and other doctors associated with the Coalition for Responsible Healthcare Guidelines, which organized the news conference, said the task force’s screening guidelines for breast, prostate, lung and cervical cancer are largely based on older research and conflict with the opinions of specialists in those areas.
For example, the task force recommends against wide use of the prostate specific antigen test, commonly known as a PSA test, for men who haven’t already had prostate cancer. Saad called that advice, which dates back to 2014, “outdated” and “overly simplistic.”
The task force’s recommendation is based on the harms of getting false positive results that lead to unnecessary biopsies and treatment, he said.
But that reasoning falsely assumes that everyone who gets a positive PSA test will automatically get a biopsy, Saad said.
“We are way beyond the era of every abnormal screening test leading to a biopsy and every biopsy leading to treatment,” he said, noting that MRIs can be used to avoid some biopsies.
“Canadian men deserve (to) have the right to decide what is important to them, and family physicians need to stop being confused by recommendations that go against logic and evidence.”
Dr. Martin Yaffe, co-director of the Imaging Research Program at the Ontario Institute for Cancer Research, raised similar concerns about the task force’s breast cancer screening guideline, which doesn’t endorse mammograms for women younger than 50.
That’s despite the fact that the U.S. task force says women 40 and older may decide to get one after discussing the risks and benefits with their primary-care provider.
The Canadian task force is due to update its guidance on breast cancer screening in the coming months, but Yaffe said he’s still concerned.
“The task force leadership demonstrates a strong bias against earlier detection of disease,” he said.
Like Saad, Yaffe believes it puts too much emphasis on the potential harm of false positive results.
“It’s very hard for us and for patients to balance this idea of being called back and being anxious transiently for a few days while things are sorted out, compared to the chance of having cancer go undetected and you end up either dying from it or being treated for very advanced disease.”
But Dr. Eddy Lang, a member of the task force, said the harms of false positives should not be underestimated.
“We’ve certainly recommended in favour of screening when the benefits clearly outweigh the harms,” said Lang, who is an emergency physician and a professor at the University of Calgary’s medical school.
“But we’re cautious and balanced and want to make sure that we consider all perspectives.”
For example, some men get prostate cancer that doesn’t progress, Lang said, but if they undergo treatments they face risks including possible urinary incontinence and erectile dysfunction.
Lang also said the task force monitors research “all the time for important studies that will change our recommendations.”
“And if one of them comes along, we prioritize the updating of that particular guideline,” he said.
The Canadian Cancer Society pulled its endorsement from the task force’s website in December 2022, saying it hadn’t acted quickly enough to review and update its breast cancer screening guidelines to consider including women between 40 and 50.
“(The Canadian Cancer Society) believes there is an obligation to ensure guidelines are keeping pace with the changing environment and new research findings to ensure people in Canada are supported with preventative health care,” it said in an emailed statement Monday evening.
Some provinces have implemented more proactive early detection programs, including screening for breast cancer at younger ages, using human papillomavirus (HPV) testing to screen for cervical cancer and implementing CT scanning to screen for lung cancer, doctors with the Coalition for Responsible Healthcare Guidelines said.
But that leads to “piecemeal” screening systems and unequal access across the country, said Dr. Shushiela Appavoo, a radiologist with the University of Alberta.
Plus, many primary-care providers rely on the national task force guidelines in their discussions with patients, she said.
“The strongest association … with a woman actually going for her breast cancer screen is whether or not her doctor recommends it to her. So if her doctor is not recommending it to her, it doesn’t matter what the provincial guideline allows,” Appavoo said.
In addition to updating its guideline for breast cancer screening this spring, the task force is due to review its guidelines for cervical cancer screening in 2025 and for lung cancer and prostate cancer screening in 2026, according to its website.
This report by The Canadian Press was first published April 16, 2024.
Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content.
Nicole Ireland, The Canadian Press
Premature opioid-related deaths doubled in Canada after the onset of COVID-19 pandemic, and more than one in four deaths occurred in young adults, a new study suggested.
“The intersection of the COVID-19 pandemic with the drug toxicity crisis in Canada has created an urgent need to better understand the patterns of opioid-related deaths across the country to inform targeted public health responses,” the study authors wrote.
Some Canadian provinces were disproportionately affected by the crisis, they noted. For example, in Alberta, close to half of all deaths among people aged 20-39 years were opioid-related.
“Although the finding that the early loss of life was increasing over time was expected, the magnitude of this burden across Canada surprised me,” lead author Shaleesa Ledlie, MPH, a PhD candidate at the Leslie Dan Faculty of Pharmacy of the University of Toronto, Toronto, Ontario, Canada, told Medscape Medical News.
In addition to the increase in Alberta, she said, “in Manitoba, opioid-related death rates and the associated years of life lost increased almost fivefold between 2019 and 2021. This really reinforces the urgency of this issue across Canada and identifies regions where focused attention might be warranted.”
The study was published online on April 15 in Canadian Medical Association Journal.
Significant Increases
Researchers conducted a repeated cross-sectional analysis of accidental opioid-related deaths from 2019 through 2021 in nine Canadian provinces and territories. All provinces and territories for which age- and sex-stratified data were available at the time of the study were included: British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, Quebec, New Brunswick, Nova Scotia, and the Northwest Territories. These areas represent 98% of Canada’s population.
Deaths were determined to be accidental or intentional by the coroner or medical examiner in each province or territory who investigated the death, according to Ledlie.
The primary outcome was the burden of premature opioid-related death, measured by potential years of life lost (YLL). The secondary outcome was the proportion of deaths attributable to opioids.
Overall, the annual YLL from opioid-related deaths doubled during the study period, from 3.5 YLL per 1000 population in 2019 to 7.0 YLL per 1000 in 2021.
In 2021, the highest burdens of death were observed among men (9.9 YLL per 1000) and young adults aged 20-29 years (12.8 YLL per 1000) and 30-39 years (16.5 YLL per 1000).
More than 70% of all opioid-related deaths occurred among men each year (73.9% in 2021), and about 25% of deaths occurred among people between the ages of 30 and 39 years (29.5% in 2021).
Geographic Variation
The annual increases by age and sex in each province and territory were generally consistent with the overall analysis. The observed changes in YLL over time varied geographically, however. They ranged from a 0.8-fold decrease in Nova Scotia (1581 YLL in 2019 to 1324 YLL in 2021) to a 4.7-fold increase in Manitoba (2434 YLL in 2019 to 11,543 YLL in 2021).
In 2021, the rate of YLL ranged from a low of 1.4 per 1000 in Nova Scotia to a high of 15.6 per 1000 in Alberta, whereas the absolute number of YLL ranged from 93 in the Northwest Territories to 111,633 in Ontario.
Between 2019 and 2021, the average percentage of all deaths attributed to opioids increased in all age groups. In 2019, 1.7% of deaths among people younger than 85 years were related to opioids. This proportion increased to 3.2% of deaths in 2021.
The largest relative increase between 2019 and 2021 (50.3%) was among young people. Opioid-attributable deaths increased from 19.3% to 29.0% among those aged 30-39 years. This change was followed by a 48.0% increase among those aged 20-29 years from 19.8% to 29.3%.
The authors noted that the study was limited by their inability to examine four provinces and territories for which the numbers of opioid-related deaths were suppressed because of small counts (ie, < 5). However, sensitivity analyses suggested that the demographic distribution of these deaths followed a pattern like that of the overall results.
More Information Needed
Commenting on the study for Medscape Medical News, S. Monty Ghosh, MD, MPH, an assistant professor at the University of Alberta, clinical assistant professor at the University of Calgary, and co-medical lead of Alberta Health Services’ Rapid Access Addiction Medicine program in Calgary, said, “The study was fairly robust in its evaluation. Their approach statistically is sound and makes sense, given the quality of data they received.” Ghosh did not participate in the analysis.
It would be important to know whether the premature deaths were polysubstance related, he noted. “More nuanced data in Alberta demonstrated that most of the deaths are related to polysubstance use on top of fentanyl. This includes alcohol, meth, as well as substance contaminants such as benzodiazepines, and more lately (outside of the research period), xylazine.”
Furthermore, Ghosh added, “It would be good to see more demographic information around the youth in Alberta. For instance, were they housed or unhoused? Are they Indigenous? Anecdotally, we know that blue-collar workers, especially those in Alberta who work in construction and oil rigs, have a disproportionate rate of substance use and at times substance death. This was seen in British Columbia and Ontario.”
What’s Being Done
The government of Alberta is responding to these data, said Ghosh. For example, in 2022, specialized funding was provided to enable young adults to access gold-standard opioid agonist treatment. The treatment was rolled out through Alberta’s Virtual Opioid Dependency Program (VODP) and other community-based addiction programs. “This [program] still needs to be more focused on homeless youth, however, who may not have access to technology or other resources.”
Furthermore, the government recently announced a $1.55-billion plan to continue building the Alberta Recovery model, he said. “This is the largest investment seen in our province. Safer supply or prescribed alternatives is very controversial in Alberta and thus is not an option available to this population.”
In addition, he said, the Ministry of Seniors and Community Social Services recently began “coordinated work with other ministries to support vulnerable and equity-deserving populations around this issue, including creating navigation centers for housing, income support, and access to treatment through the VODP.”
Ledlie noted that various policies and programs have been developed in response to the ongoing drug toxicity crisis. Some were included in a recent review that her team conducted to summarize the evidence from Canadian safer opioid supply programs. “We found that in general, these programs had positive impacts on clients, including reduced rates of opioid toxicities and improvements in quality of life.”
“Because most healthcare is coordinated at the provincial or territorial level, the investments into, and accessibility of, treatment and harm-reduction services tend to vary across Canada,” she said. “Even in regions where these programs exist, we know that they are not always accessible for various reasons, such as a lack of resources preventing widespread expansion and geographic barriers in more remote and rural regions.”
“One example of a simple yet life-saving harm reduction measure that has been effectively implemented by most provincial and territorial governments is the availability of publicly funded naloxone kits,” she added. “Given the widespread societal impacts of opioid toxicities described in our study, we believe it is pivotal for all levels of government to coordinate to ensure equitable access to evidence-based services across the country, while still providing the opportunity to tailor and adapt those responses to the unique needs of local communities.”
The study was supported by grants from the Ontario Ministry of Health and the Canadian Institutes of Health Research. Ledlie is supported by an Ontario Graduate Scholarship and the Network for Improving Health Systems Trainee Award. Ledlie and Ghosh declared no relevant financial relationships.
Marilynn Larkin, MA, is an award-winning medical writer and editor whose work has appeared in numerous publications, including Medscape Medical News and its sister publication MDedge, The Lancet (where she was a contributing editor), and Reuters Health.
Aaron Sluchinski adds Kyle Doering to lineup for next season – The Grand Slam of Curling
Paleontologists unearth what may be the largest known marine reptile – Science Daily
Jacobs takes over rink previously skipped by Bottcher – TSN
Silver investment demand jumped 12% in 2019
12 Bizarre Things People Did Just To Make Social Media Content
Global Media Markets, 2015-2020, 2020-2025F, 2030F – TV and Radio Broadcasting, Film and Music, Information Services, Web Content, Search Portals And Social Media, Print Media, & Cable – GlobeNewswire
-
Business23 hours ago
Firefighters battle wildfire near Edson, Alta., after natural gas line rupture – CBC.ca
-
Tech16 hours agoiPhone 15 Pro Desperado Mafia model launched at over ₹6.5 lakh- All details about this luxury iPhone from Caviar – HT Tech
-
Sports16 hours ago
Lululemon unveils Canada's official Olympic kit for the Paris games – National Post
-
Politics22 hours ago
Trump gave MAGA politicians permission to move left on abortion. Some are taking it. – Semafor
-
Politics23 hours ago
Anti-Trump Republican Larry Hogan navigates dangerous political terrain in pivotal Senate contest – Toronto Star
-
Science19 hours ago
Astronomers discover Milky Way's heaviest known black hole – Xinhua
-
News23 hours ago
'Terrific news': Chief economist reacts to latest inflation data – BNN Bloomberg
-
Business21 hours ago
Traders Place Bets On $250 Oil – OilPrice.com
